Anebulo Pharmaceuticals (ANEB) Competitors $1.01 -0.03 (-2.88%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.02 +0.01 (+0.99%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. DBVT, IPHA, FULC, NBTX, ACTU, MOLN, RZLT, ACIU, TARA, and DMACShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include DBV Technologies (DBVT), Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Nanobiotix (NBTX), Actuate Therapeutics (ACTU), Molecular Partners (MOLN), Rezolute (RZLT), AC Immune (ACIU), Protara Therapeutics (TARA), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. DBV Technologies Innate Pharma Fulcrum Therapeutics Nanobiotix Actuate Therapeutics Molecular Partners Rezolute AC Immune Protara Therapeutics DiaMedica Therapeutics Anebulo Pharmaceuticals (NASDAQ:ANEB) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment. Do insiders and institutionals hold more shares of ANEB or DBVT? 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer ANEB or DBVT? Anebulo Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 692.08%. DBV Technologies has a consensus price target of $22.50, indicating a potential upside of 181.95%. Given Anebulo Pharmaceuticals' higher probable upside, equities analysts plainly believe Anebulo Pharmaceuticals is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00DBV Technologies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, ANEB or DBVT? Anebulo Pharmaceuticals has higher earnings, but lower revenue than DBV Technologies. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.28-3.61DBV Technologies$15.73M10.44-$72.73M-$5.00-1.60 Which has more volatility & risk, ANEB or DBVT? Anebulo Pharmaceuticals has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Does the MarketBeat Community favor ANEB or DBVT? DBV Technologies received 396 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.00% of users gave Anebulo Pharmaceuticals an outperform vote while only 54.22% of users gave DBV Technologies an outperform vote. CompanyUnderperformOutperformAnebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00%DBV TechnologiesOutperform Votes40554.22% Underperform Votes34245.78% Is ANEB or DBVT more profitable? Anebulo Pharmaceuticals has a net margin of 0.00% compared to DBV Technologies' net margin of -815.73%. DBV Technologies' return on equity of -106.07% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -119.54% -108.08% DBV Technologies -815.73%-106.07%-76.17% Does the media favor ANEB or DBVT? In the previous week, DBV Technologies had 4 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for DBV Technologies and 1 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.00 beat DBV Technologies' score of -0.23 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Anebulo Pharmaceuticals Positive DBV Technologies Neutral SummaryDBV Technologies beats Anebulo Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.50M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-3.616.8921.8417.80Price / SalesN/A230.57380.2597.71Price / CashN/A65.6738.2634.64Price / Book6.735.936.443.98Net Income-$8.20M$142.99M$3.22B$247.73M7 Day Performance3.57%4.43%2.85%1.80%1 Month Performance-42.94%-12.72%-8.66%-6.97%1 Year Performance-63.27%-9.42%11.46%1.29% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.7933 of 5 stars$1.01-2.9%$8.00+692.1%-66.3%$41.50MN/A-3.614Short Interest ↓Positive NewsGap UpDBVTDBV Technologies2.6337 of 5 stars$7.79+6.4%$22.50+188.8%+17.4%$160.23M$15.73M-1.7380Earnings ReportAnalyst ForecastShort Interest ↑IPHAInnate Pharma1.98 of 5 stars$1.90+1.3%$11.50+505.3%-17.9%$159.28M$12.63M0.00220Positive NewsGap UpFULCFulcrum Therapeutics2.0112 of 5 stars$2.92+8.6%$8.63+195.4%-54.0%$157.62M$80M-9.42100Short Interest ↓News CoverageGap UpNBTXNanobiotix1.812 of 5 stars$3.33flat$8.00+140.2%-37.9%$156.95M$-11,609,000.000.00100ACTUActuate TherapeuticsN/A$8.00+4.4%$20.00+150.0%N/A$156.26MN/A0.0010News CoverageGap UpMOLNMolecular Partners1.6145 of 5 stars$3.86-0.3%$12.00+210.9%+1.5%$155.85M$4.97M-1.80180Positive NewsRZLTRezolute2.8906 of 5 stars$2.57+4.0%$24.38+848.4%-15.1%$155.58MN/A-2.1140Positive NewsGap UpACIUAC Immune2.5357 of 5 stars$1.52-2.6%$12.00+689.5%-38.8%$152.62M$27.31M-3.30140Analyst RevisionNews CoveragePositive NewsTARAProtara Therapeutics1.8053 of 5 stars$4.14+5.9%$22.50+443.5%+42.9%$152.22MN/A-1.4730Analyst ForecastNews CoverageGap DownDMACDiaMedica Therapeutics1.0969 of 5 stars$3.54+2.0%$8.00+126.0%+36.2%$151.71MN/A-6.3220Short Interest ↑News CoverageGap Up Related Companies and Tools Related Companies DBV Technologies Alternatives Innate Pharma Alternatives Fulcrum Therapeutics Alternatives Nanobiotix Alternatives Actuate Therapeutics Alternatives Molecular Partners Alternatives Rezolute Alternatives AC Immune Alternatives Protara Therapeutics Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANEB Stock Free ANEB Stock Alerts